Botulinum Neurotoxin (BoNT) therapeutics: Time to think outside the BoNT?
by Joseph C. Larsen
The Botulinum J. (TBJ), Vol. 1, No. 3, 2009

Abstract: The development of small molecule inhibitors of Botulinum Neurotoxin (BoNT) has been a robust focus of biodefence research funding. Despite an intense effort, no compounds have been identified that would be suitable for extensive preclinical testing. Due to the emphasis on BoNT inhibitor development, research into other aspects of toxin biology may have been overlooked. In particular, the molecular mechanisms that neuronal cells utilise to respond to the presence of BoNT has been an area that, to date, is a significant gap in our understanding of BoNT pathogenesis. An elucidation of these pathways could lay the foundation for the identification of novel targets for the treatment of botulism.

Online publication date: Wed, 17-Feb-2010

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the The Botulinum J. (TBJ):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com